ARCHIVES

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

This article is from The Cancer Letter archive.

Vol. 18 No. 34 | September 4, 1992

Download PDF Visit The Full Archive

Related Articles

Ten Is The New 12: Medicare Lowers Hemoglobin Targets For ESA Use.

August 3, 2007

Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease

April 25, 2014

News Analysis: IOM Report A Case Study In Communications Disaster

February 5, 1999

NCAB Committee Approves Recompletion Of Support Contracts

October 7, 1988

FDA Advisors Okay NCI Toxicology Proposals, Write New Clinical Guidelines, Approve AIN DA

October 19, 1979

Interim Results Show Vaccine Lowers Breast Cancer Recurrence

December 30, 2011